TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02172729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adductor canal block with 20 ml lidocaine, single bolus
Description: Duration of an adductor canal block with 20 ml lidocaine, single bolus, administered as 5 or 15 mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adductor canal block with 20 ml lidocaine, single bolus
Description: Duration of an adductor canal block with 20 ml lidocaine, single bolus, administered as 5 or 15 mg/ml
Study: NCT04760873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: cryotherapy is a freeze spray that will be applied to GAVE for bleeding
Study: NCT01185249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Weigh subjects on a scale in the standing position
Description: Subjects will stand on a scale in the mornings, and the evenings for 3 days while hospitalized.
Study: NCT04245527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Joovv Infrared Light Device
Description: Joovv is the leading manufacturer of personal, in-home red light therapy devices
Study: NCT01789853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Walking
Description: 8 weeks high intensity walking training over multiple stepping tasks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Regular physical therapy for 8 weeks
Study: NCT00302718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician-level financial incentives
Description: Enrolled physician participants are eligible to receive financial incentives and audit and feedback reports based on their performance during a 4-month interval on the hypertension care study outcomes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice-level financial incentives
Description: Enrolled practices (physician physicians and non-physician primary care personnel) are eligible to receive financial incentives and audit and feedback reports based on the performance of the practice during a 4-month interval on the hypertension care study outcomes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician- and practice-level financial incentives
Description: Enrolled participants are eligible to receive financial incentives and audit and feedback reports based on performance during a 4-month interval on the hypertension care study outcomes. This arm tests the effect of combined financial incentives (physician-level incentives and practice-level incentives).
Study: NCT05311397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A166
Description: A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A166
Description: A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.
Study: NCT03440385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT03521193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: patent foramen ovale closure
Description: Pts undergoing PFO closure will receive 2-months of DAPT and 6 months of aspirin after patent foramen ovale (PFO) closure; they will be compared to healthy subjects on aspirin treatment
Study: NCT02207296

Intervention type: DEVICE
Group type: OTHER
Intervention: Plethysmographic variability index
Study: NCT00530309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK716155 for injection
Description: GSK716155 will be available with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks.
Study: NCT04633330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHCC®capsules
Description: AHCC®capsules, a standardized extract of cultured Lentinula edodes mycelia (ECLM) TID for 6 months after enrolment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simulation of AHCC®capsules
Description: TID for 6 months after enrolment. A compensation of AHCC®is provided to participant from control arm when HR-HPV positive at 6 months after enrolment.
Study: NCT00027599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: prostatic acid phosphatase-sargramostim fusion protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro-treated peripheral blood stem cell transplantation
Study: NCT00642486

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Portable (Embla Embletta X30 system and Respironic REMStar Auto M series with CFlex)
Description: portable, home-based using the Embla Embletta X30 system as the diagnostic device and the Respironic REMStar Auto M series with CFlex as the PAP titration device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard polysomnography (PSG)
Description: laboratory-based testing
Study: NCT01599286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbaglu
Description: Carbaglu Chemical Composition: N-carbamoyl-L-glutamic acid (NCG)~The daily dose will be 150 mg/kg/ day or 3.3 g/m2/day for patients \>15 kg and will be administered for 7 days or until discharge, whichever is sooner. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube. Standard of care will prevail when choosing the mode of drug administration.~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast-push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo that looks/tastes the same as NCG and is administered on the same schedule as the NCG intervention
Study: NCT00871026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthodontic treatment with customized archwires
Description: orthodontic treatment with customized archwires

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic treatment with prefabricated archwires
Description: orthodontic treatment with prefabricated archwires
Study: NCT01480687

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA-EPA
Description: 1800 mg/day
Study: NCT00530309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will also receive placebo.
Study: NCT03400254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib will be administered intravenously on a weekly dosing schedule at 150 mg IV.~Within 3 days prior to GED dosing the patient must have an ANC \>1.0 x 109/L and platelet count \> 75 x 109/L. If hematologic toxicity persists, treatment should be delayed by one week and the complete blood cell count with differential and platelet count repeated. Treatment may be delayed for up to 4 consecutive weeks (28 days). If after 28 days of delay all hematologic toxicity has still not resolved to normal and non-hematologic toxicity has not resolved to \<grade 1 then any further treatment with GED should be stopped.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib will be administered intravenously on a weekly dosing schedule at 150 mg IV.~Within 3 days prior to GED dosing the patient must have an ANC \>1.0 x 109/L and platelet count \> 75 x 109/L. If hematologic toxicity persists, treatment should be delayed by one week and the complete blood cell count with differential and platelet count repeated. Treatment may be delayed for up to 4 consecutive weeks (28 days). If after 28 days of delay all hematologic toxicity has still not resolved to normal and non-hematologic toxicity has not resolved to \<grade 1 then any further treatment with GED should be stopped.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib will be administered intravenously on a weekly dosing schedule at 150 mg IV.~Within 3 days prior to GED dosing the patient must have an ANC \>1.0 x 109/L and platelet count \> 75 x 109/L. If hematologic toxicity persists, treatment should be delayed by one week and the complete blood cell count with differential and platelet count repeated. Treatment may be delayed for up to 4 consecutive weeks (28 days). If after 28 days of delay all hematologic toxicity has still not resolved to normal and non-hematologic toxicity has not resolved to \<grade 1 then any further treatment with GED should be stopped.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib will be administered intravenously on a weekly dosing schedule at 150 mg IV.~Within 3 days prior to GED dosing the patient must have an ANC \>1.0 x 109/L and platelet count \> 75 x 109/L. If hematologic toxicity persists, treatment should be delayed by one week and the complete blood cell count with differential and platelet count repeated. Treatment may be delayed for up to 4 consecutive weeks (28 days). If after 28 days of delay all hematologic toxicity has still not resolved to normal and non-hematologic toxicity has not resolved to \<grade 1 then any further treatment with GED should be stopped.
Study: NCT05300061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Values Intervention
Description: A 15 minute personal values intervention. Aim is to help participants clarify their own values around flying and promote committed action towards airplanes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prosocial Values Intervention
Description: A 15 minute prosocial values intervention. Aim is to help participants clarify their prosocial values around flying and promote committed action towards airplanes.
Study: NCT00944333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 300-600 loading dose 75 mg/die for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 300-600 loading dose 75 mg/die for 12 months
Study: NCT02618018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AT TORBI 709M
Description: Cataract surgery with AT TORBI 709M 4-haptic toric IOL
Study: NCT04035668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remibrutinib
Description: Remibrutinib 100 mg was administered orally as two 50 mg hard gelatin capsules. Patients in the remibrutinib 100 mg bid dose group took 2 capsules of active medication in the morning and 2 capsules of active medication in the evening. Patients in the remibrutinib 100 mg qd dose group took 2 capsules of active medication in the morning and 2 capsules of the placebo in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remibrutinib
Description: Remibrutinib 100 mg was administered orally as two 50 mg hard gelatin capsules. Patients in the remibrutinib 100 mg bid dose group took 2 capsules of active medication in the morning and 2 capsules of active medication in the evening. Patients in the remibrutinib 100 mg qd dose group took 2 capsules of active medication in the morning and 2 capsules of the placebo in the evening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered orally as two hard gelatin capsules. Patients in the placebo dose group took 2 capsules of placebo in the morning and 2 capsules of placebo in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was administered orally as two hard gelatin capsules. Patients in the placebo dose group took 2 capsules of placebo in the morning and 2 capsules of placebo in the evening.
Study: NCT01691352

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wick dressing
Description: Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2cm wound, a single suture will be placed in the middle). A moist, saline/betadine soaked gauze will then be gently packed into the wound spaces, on either side of the sutures. The gauze will be packed into the wound to the depth of ½ a cm, or ½ of the wound depth, whichever is greater. A single dry piece of gauze will then be secured over the top of the wound. Dressings and packing will be removed by the surgical team on post-operative day 2

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No Wick
Description: Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2 cm wound, a single suture will be placed in the middle). A single piece of dry gauze will then be secured over the top of the wound. Dressings will be removed by the surgical team on post-operative day 2
Study: NCT02571751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UNIGEL Silicone Gel-Filled Breast Implant
Study: NCT00579501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 1.5 mg/m\^2 over a 24-hour iv infusion every 3 weeks for a minimum of 3 and a maximum of 6 cycles of trabectedin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg iv will be administered within 30 minutes before start of each trabectedin iv infusion
Study: NCT01549743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200mg will be administered orally twice a day for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: Rebamipide 100mg will be administered orally three times a day for 3 days
Study: NCT04528706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-102
Description: Once-daily dosing with a volume specified by the pharmacokineteic specialist to achive the desired plasma exposure. Min-102 Oral suspension, strength 15mg/ml.
Study: NCT03915340

Intervention type: DRUG
Group type: OTHER
Intervention: Propafenone
Description: Propafenone is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 300 mg of propafenone hydrochloride.

Intervention type: DRUG
Group type: OTHER
Intervention: Propafenone
Description: Propafenone is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 300 mg of propafenone hydrochloride.

Intervention type: DRUG
Group type: OTHER
Intervention: Rytmonorm
Description: Rytmonorm is manufactured by Famar Lyon, France (MAH: Mylan Healthcare GmbH, Germany). Each tablet contains 300 mg of propafenone hydrochloride.

Intervention type: DRUG
Group type: OTHER
Intervention: Rytmonorm
Description: Rytmonorm is manufactured by Famar Lyon, France (MAH: Mylan Healthcare GmbH, Germany). Each tablet contains 300 mg of propafenone hydrochloride.
Study: NCT00465816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix (Meningococcal vaccine 134612)
Description: Single dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nimenrix (Meningococcal vaccine 134612)
Description: Single dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix
Description: 3-dose intramuscular injection. Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Twinrix
Description: 3-dose intramuscular injection. Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.
Study: NCT01129232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAD-alum
Description: 20 µg of GAD-alum injected sc after the biopsy, and repeated after one month

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injected after the biopsy and repeated after one month (similar to the GAD-alum-arm)
Study: NCT00703950

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cup feeding
Description: Method to feed: cup. This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using cup

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bottle feeding
Description: bottle feeding This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using bottle
Study: NCT02011698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lichtenstein technique groin hernia repair with mesh. Use of absorbale sutures for mesh fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein technique groin hernia repair with mesh. Use of non absorbable sutures for mesh fixation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lichtenstein technique groin hernia repair with mesh. Use of fibrin biological glue for mesh fixation
Study: NCT04583046

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline inhalation
Description: When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply normal saline inhalation for control group and measure ABGA at the time of 20 min after normal saline inhalation has finished (T2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost inhalation
Description: When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply iloprost inhalation for iloprost group and measure ABGA at the time of 20 min after iloprost inhalation has finished (T2).
Study: NCT02552186

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caliper measurement
Description: Clinical caliper measurements will be taken and used to calculate the Clinical PI
Study: NCT02504723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyanoacrylate
Description: The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
Study: NCT01480687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofibrate
Description: 100 mg/day
Study: NCT03763578

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Licorice
Description: Natural herbal product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Licorice
Description: Natural herbal product
Study: NCT00772759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199 Turbuhaler®
Description: 240, 720 and 2160 μ g, single and multiple (o.d. for 12 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Turbuhaler®
Description: single and multiple (o.d. for 12 days)
Study: NCT00654108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: 500 milligrams(mg) will be administered orally twice daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: 500 milligrams(mg) will be administered orally twice daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: 500 milligrams(mg) will be administered orally twice daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: 500 milligrams(mg) will be administered orally twice daily for 5 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peru-15-pCTB
Description: Live attenuated oral combined ETEC-cholera (Peru-15 pCTB) vaccine co-administered with bicarbonate buffer solution; vaccine dose levels 1 X 10\^7; 1 X 10\^8; 1 X 10\^9; and 1 X 10\^10.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peru-15-pCTB
Description: Live attenuated oral combined ETEC-cholera (Peru-15 pCTB) vaccine co-administered with bicarbonate buffer solution; vaccine dose levels 1 X 10\^7; 1 X 10\^8; 1 X 10\^9; and 1 X 10\^10.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peru-15-pCTB
Description: Live attenuated oral combined ETEC-cholera (Peru-15 pCTB) vaccine co-administered with bicarbonate buffer solution; vaccine dose levels 1 X 10\^7; 1 X 10\^8; 1 X 10\^9; and 1 X 10\^10.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peru-15-pCTB
Description: Live attenuated oral combined ETEC-cholera (Peru-15 pCTB) vaccine co-administered with bicarbonate buffer solution; vaccine dose levels 1 X 10\^7; 1 X 10\^8; 1 X 10\^9; and 1 X 10\^10.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
Description: Buffer solution: 2.5 grams (g) Sodium Bicarbonate powder, 1.65 g Ascorbic Acid and 25 mg Aspartame, in 100 milliliters (mL) water for injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
Description: Buffer solution: 2.5 grams (g) Sodium Bicarbonate powder, 1.65 g Ascorbic Acid and 25 mg Aspartame, in 100 milliliters (mL) water for injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
Description: Buffer solution: 2.5 grams (g) Sodium Bicarbonate powder, 1.65 g Ascorbic Acid and 25 mg Aspartame, in 100 milliliters (mL) water for injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
Description: Buffer solution: 2.5 grams (g) Sodium Bicarbonate powder, 1.65 g Ascorbic Acid and 25 mg Aspartame, in 100 milliliters (mL) water for injection.
Study: NCT02235324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01549743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib plus Rebamipide
Description: Celecoxib plus Rebamipide same way as arm: celecoxib and arm: rebamipide
Study: NCT01370057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thoraco-lumbo-sacral Orthosis
Description: Treatment with Thoraco-lumbo-sacral Orthosis for Adolescent Idiopathic Scoliosis